|
Video: What is a Stock Split?
|
|
Evaxion Biotech is a clinical-stage artificial intelligence (AI)-immunology platform company using its AI technology to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Co.'s three AI platforms include: PIONEER, Co.'s immuno-oncology platform; EDEN, Co.'s bacterial disease platform; and RAVEN, Co.'s viral disease platform. Co. is focused on using PIONEER for the development of patient-specific immunotherapies for various cancers and using EDEN to develop immunotherapies for bacterial diseases. According to our Evaxion Biotech A/S stock split history records, Evaxion Biotech A/S has had 1 split. | |
|
Evaxion Biotech A/S (EVAX) has 1 split in our Evaxion Biotech A/S stock split history database. The split for EVAX took place on January 22, 2024. This was a 1 for 10 reverse split, meaning for each 10 shares of EVAX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Evaxion Biotech A/S conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Evaxion Biotech A/S stock split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Evaxion Biotech A/S shares, starting with a $10,000 purchase of EVAX, presented on a split-history-adjusted basis factoring in the complete Evaxion Biotech A/S stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/08/2021 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$99.50 |
|
End price/share: |
$4.12 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.86% |
|
Average Annual Total Return: |
-62.94% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$413.96 |
|
Years: |
3.21 |
|
|
|
Date |
Ratio |
01/22/2024 | 1 for 10 |
|
|